Parecoxib

Parecoxib is a water-soluble, injectable prodrug, specifically derived from its active form, valdecoxib. Commercially introduced as Dynastat within the European Union, parecoxib holds the distinction of being a COX-2 selective inhibitor. This positions it within the same pharmaceutical category as other notable drugs such as celecoxib (known by its brand name Celebrex) and rofecoxib (trademarked as Vioxx).

Error creating thumbnail:

Parecoxib

Parecoxib molecule ball

One of the primary advantages of parecoxib is its injectable nature, which offers clinicians the flexibility to administer it during perioperative periods when patients may not be in a position to consume oral medications. It has gained regulatory approval across a significant portion of Europe and is utilized primarily for the short-term management of perioperative pain. This aligns with the function of ketorolac (commercially known as Toradol) in the United States.

An essential distinction between parecoxib and ketorolac revolves around their impact on platelet functionality. While the former doesn't influence platelet function, thereby not increasing the risk of perioperative bleeding, ketorolac can augment surgical bleeding risk. Furthermore, ketorolac has a noted elevated gastrointestinal toxicity when juxtaposed against a majority of nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naprosyn. Notably, despite its drawbacks, ketorolac remains the sole injectable NSAID approved in the U.S., whereas many European countries have prohibited its use, citing apprehensions related to postoperative complications, including bleeding and the potential emergence of gastric ulcers.

The regulatory landscape for parecoxib in the United States experienced a setback in 2005 when the U.S. Food and Drug Administration (FDA) issued a non-approval verdict for its commercialization. Although official reasons behind this decision weren't publicly disclosed, there's speculation around a study that highlighted an elevated risk of heart attacks following cardiac bypass surgery, especially when parecoxib was administered in higher doses for postoperative pain management. Another vital aspect to consider is the association of severe allergic reactions, including Stevens-Johnson Syndrome and Lyell Syndrome, with valdecoxib, which is the metabolized form of parecoxib. Due to such concerns, parecoxib hasn't been sanctioned for post-cardiac surgery utilization within Europe.

In the wake of the Vioxx controversy, the FDA's reluctance to approve parecoxib was likely influenced by external political pressures. Since that period, no COX-2 selective inhibitor has garnered approval in the U.S., even though parecoxib continues to maintain a satisfactory safety profile within European regions. Despite efforts, obtaining the scientific logic or the probable absence of it behind the FDA's non-approval remains challenging, largely due to confidentiality constraints.

See Also

• COX-2 selective inhibitor
• Discovery and development of cyclooxygenase 2 inhibitors
• Valdecoxib

• Dailymed label info on Parecoxib
• FDA Parecoxib

Parecoxib Resources
Latest articles Most recent articles Ongoing trials	Wikipedia